Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture Ibuprofen capsules. Aurobindo’s Ibuprofen capsules are the generic equivalent of Pfizer’s Advil Liqui-Gels capsules. The product will be launched in September 2018.
Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, muscular aches, and minor pain of arthritis. It is also used to reduce fever and to relieve from minor aches and pain due to common cold or flu.
The estimated market size of Ibuprofen capsules OTC is $ 164 million for the 12 months ended March 2018, according to Nielsen data. This is the 143rd ANDA (including 19 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, used for manufacturing oral products.